Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Sponsor: Ascentage Pharma Group Inc.
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
Official title: A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Key Details
Gender
FEMALE
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-08-09
Completion Date
2026-12
Last Updated
2025-12-16
Healthy Volunteers
No
Conditions
Interventions
APG-2575
Take orally once daily (QD) for 12 weeks.
Placebo
Take orally once daily (QD) for 12 weeks.
Locations (1)
Renji Hospital Shanghai Jiaotong University School of Medical
Shanghai, Shanghai Municipality, China